Question explored with the scientific record
Conversation so far
- 1 Is the Medicare GUIDE pilot program helpful for dementia
- 2 Are there any studies measuring GUIDE outcomes for dementia patients?
Answered on this page ↓
Are there any studies measuring GUIDE outcomes for dementia patients?
The short version: no studies of GUIDE outcomes were retrieved, and the new evidence does not change that — but it does show what a real GUIDE study would need to measure.
The retrieved evidence still contains nothing about the Medicare GUIDE pilot program. The closest match is a study showing that frailty predicts much higher post-surgical costs — frail patients cost $110,702 over six months versus $33,453 for non-frail [1]. That is not a GUIDE study, but it points to what GUIDE would need to prove: that its care coordination actually lowers those costs and improves outcomes for the dementia population it targets.
The other records are off-topic: a cost analysis of cancer of unknown primary [2], a COVID readmission study [3], a commentary on beta-blocker adherence that mentions a different "GUIDE-IT" trial for heart failure [4], and a stent reimbursement analysis [5]. None of these evaluate the GUIDE dementia program.
What this retrieval confirms is that the question remains unanswered. A proper evaluation would compare dementia patients in GUIDE to those receiving usual Medicare on hospitalization rates, nursing home placement, caregiver burden, and mortality. No such study appears here. The frailty cost data [1] suggests the stakes are high — frail older adults already cost the system far more than Medicare's diagnosis-based payments capture — but that is context, not evidence for or against GUIDE.
My call: the evidence does not support any conclusion about GUIDE outcomes. Confidence: not clear — the retrieval simply did not reach the relevant literature.
Sources used 5
-
Frailty predicts increased hospital and six-month healthcare cost following colorectal surgery in older adults
In older adults undergoing elective colorectal surgery, preoperative frailty burden independently predicts higher hospital and six-month healthcare costs, driven by increased postdischarge resource use (institutionalization and readmissions), and it outperforms Medicare DRG paym…
DOI: 10.1016/j.amjsurg.2011.06.017 -
Acups (adenocarcinoma of unknown primary site): A clinical and cost benefit analysis
A retrospective, single-center analysis of 287 patients with adenocarcinoma of unknown primary site (ACUPS) evaluating clinical characteristics, diagnostic workups, survival, and a cost-benefit analysis of investigations, concluding low ante-mortem identification rates, heteroge…
DOI: 10.1016/0360-3016(87)90317-8 -
Factors Associated With Readmission in the United States Following Hospitalization With Coronavirus Disease 2019
A large retrospective cohort study of 29,659 adults hospitalized with COVID-19 in 297 US hospitals across 40 states evaluating the 30‑day readmission rate (3.6%) and identifying demographic, regional, and comorbidity risk factors associated with readmission and mortality upon re…
DOI: 10.1093/cid/ciab464 -
“Drugs Do Not Work on Patients Who Do Not Take Them” Can We Do Better in Patient Adherence?
An editorial commentary highlighting persistent under-utilization of guideline-directed medical therapy beta-blockers for heart failure with reduced ejection fraction, analyzing CMS-based adherence data from Loop et al. and proposing multidisciplinary, educational, and policy-dr…
DOI: 10.1016/j.cardfail.2019.04.003 -
Mis-Alignment of Clinical Goals and Financial Incentives in Coronary Stent Revascularizations Adversely Affects Patient Outcomes
A commentary argues that misaligned Medicare financial incentives encourage unnecessary coronary stent procedures and that replacing visual angiographic assessment with FFR-guided PCI would improve patient outcomes and reduce CMS expenditures.
DOI: 10.18103/mra.v12i6.5384